PRS:提高治疗效率和患者生活质量,针对烧伤后神经疼痛成因来镇痛!

2021-03-15 MedSci原创 MedSci原创

该研究提出了由直接神经损伤、神经压迫、电损伤和继发于全身损伤的神经功能障碍组成的分类方法,可指导患者的治疗和研究方法,以改善烧伤相关神经疼痛的疼痛结局。

烧伤患者会有与损伤本身相关的急性疼痛、与清创术和植入术相关的急性疼痛,可能还有愈合阶段的疼痛。烧伤医生精通适当采取药物治疗缓解急性疼痛。但对于烧伤患者出院时有慢性神经性疼痛的机制,人们不太了解,也不太清楚。这种慢性疼痛会影响重建过程。

了解神经损伤的机制可能有助于治疗烧伤相关的神经疼痛。这一建议的分类是基于神经损伤的原因,旨在加强对烧伤相关神经疼痛的理解和管理

这项回顾性调查包括2014-2019年在烧伤中心就诊的15岁及以上患者。烧伤相关的神经疼痛是患者报告的,临床评估为烧伤后6个月或更长时间的疼痛,与先前存在的疾病/药物无关。

疼痛分类包括直接神经损伤、神经压迫、电损伤和继发于全身损伤的神经功能障碍。使用52个变量对这四个类别进行了组间统计分析。

在1880例连续烧伤患者中,113例出现烧伤相关的神经疼痛(患病率为6%),符合分类标准。

113例烧伤相关神经损伤患者中,47例为直接神经损伤,12例为神经压迫,7例为电损伤,47例为全身损伤继发神经功能障碍。

直接神经损伤与持续性疼痛症状(p<0.001)和瘙痒(p<0.001)显著相关(表3)。神经修复与慢性疼痛的缓解显著相关(p<0.001)(表4)。

神经压迫与烧伤总面积百分比增加(p=0.019)、烧伤前滥用物质(p=0.005)和更多的外科手术(p<0.001)显著相关(表2)。与神经压迫相关的疼痛特征是Tinel征阳性(p<0.001)、枪击痛(p<0.001)、麻木(p=0.003)和间歇性症状(p<0.001)(表3)。神经受压者筋膜切除显著增加(p=0.002)(表5)。羟色胺-去甲肾上腺素再摄取抑制剂(p<0.001)、阿片类药物(p<0.001)和神经松解治疗(p<0.001)在神经压迫相关疼痛中的使用显著较高(表4和表6)。压迫损伤与这些患者的总体并发症显著相关(p=0.003)(表7)。

与其他类别相比,电损伤与Tinel阳性体征(p<0.001)和间歇性症状(p=0.002)显著相关(表3)。电击伤患者截肢(p=0.002)和筋膜切开术(p<0.001)明显增多。在这一类别中,压迫,然后是神经松解,在治疗疼痛方面明显更高(p<0.001)(表4)。

全身损伤继发的神经功能障碍与较少的三度烧伤显着相关(p=0.002)(表2)。疼痛特征包括与其他类别相比,治疗后长期疼痛评分降低(p<0.001)、无体征和症状(tinel征)(p<0.001)、刺痛(p<0.001)、麻木(p<0.001)、刺痛(p<0.001)和瘙痒(p<0.001)。与筋膜切除(p=0.004)和皮肤移植(p<0.001)相比,外科烧伤治疗与全身损伤相关的明显较少。与其他类型的疼痛相比,全身损伤患者没有截肢(p=0.004)(表5)。与其他类型的疼痛[激光(p=0.002)和物理治疗/职业治疗(p<0.001)]相比,全身损伤所需的神经疼痛的手术和非手术治疗要少得多。与其他类型的疼痛相比,全身损伤患者没有神经释放(p<0.001)。

该研究提出了由直接神经损伤、神经压迫、电损伤和继发于全身损伤的神经功能障碍组成的分类方法,可指导患者的治疗和研究方法,以改善烧伤相关神经疼痛的疼痛结局。

 

原始文献:

Klifto Kevin M,Hultman C Scott,Dellon A Lee,Nerve Pain after Burn Injury: A Proposed Etiology-Based Classification.[J] .Plast Reconstr Surg, 2021, 147: 635-644.

DOI: 10.1097/PRS.0000000000007639

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-04-02 kzlchina
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-04-12 147fbc99m40(暂无昵称)

    优秀

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-04-07 ms6000000953271194

    学习到了很多

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-03-29 ptwins

    一积分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-03-17 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-03-15 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1669047, encodeId=acc5166904e32, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Fri Apr 02 22:40:27 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956182, encodeId=d23b95618233, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0d05259423, createdName=147fbc99m40(暂无昵称), createdTime=Mon Apr 12 15:44:10 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954354, encodeId=8734954354c5, content=学习到了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/487c229efac94876b49c9c30dc3c5978/bbe6ad0e02094100bdacfef6b7ef7f01.jpg, createdBy=0e515477589, createdName=ms6000000953271194, createdTime=Wed Apr 07 01:45:54 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952086, encodeId=e38195208631, content=一积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a355398176, createdName=ptwins, createdTime=Mon Mar 29 16:40:37 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355356, encodeId=bf0e1355356ea, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 17 03:40:27 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032836, encodeId=25bc1032836e8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Mar 15 15:40:27 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948355, encodeId=d433948355e2, content=关注提高患者生存质量, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40772833234, createdName=840322247, createdTime=Mon Mar 15 14:17:37 CST 2021, time=2021-03-15, status=1, ipAttribution=)]
    2021-03-15 840322247

    关注提高患者生存质量

    0

相关资讯

烧伤超人阿宝:如果我倒下,再不能起来

来源:烧伤超人阿宝 回北京的车上,手机突然叮当叮当响个不停,不知道多少个亲朋好友在问我同一个问题:你没事吧?伤的重不重? 我莫名其妙,追问了一下,原来,在微博和微信朋友圈里面,都在大肆传播这样一个谣言: 幸亏,我刚探望父母回来,父母知道我没有事,否则的话,不知道得多担惊受怕。 几天前,一个名为“中国最缺缺德的人”的短视频,在微信和微博被各种营销号

陈劲松: 我在烧伤科做医生

我在烧伤科做医生

Cell Death Dis:烧伤后脂肪褐变引发肝脂肪变

烧伤患者会经历体内高代谢,进而会出现肝脂肪变性,这与受伤后发生肝衰竭及不良预后有关。而且烧伤患者还会经历白色脂肪组织(WAT)褐色变,这与烧伤后的恶病质调节和持续的高代谢有关。尽管烧伤后常出现肝脂肪变性和WAT褐色变两种临床表现,但对其潜在机制仍知之甚少。在本研究中,研究人员发现烧伤所引起的WAT褐色变及其相关的脂解作用的增加会导致小鼠肝脂肪变性的加速进展。敲除白介素6(IL-6)和解偶联蛋白1(

Cell Death Dis:研究揭示肥胖者烧伤后肝脏脂肪浸润的机制

严重烧伤的病态肥胖患者临床结局不佳,代谢后果加重,多器官功能障碍/衰竭发生率更高,死亡率明显增加。而这些不良结局的潜在机制知之甚少。由于肝脏是中枢代谢器官之一,研究假设肥胖患者的热损伤导致脂肪分解和肝脏脂肪浸润明显增加,导致肝细胞和细胞器的严重改变,从而导致肝损伤和代谢功能障碍严重增加。 使用全身20%表面积烧伤的肥胖小鼠模型进行实验。将C57BL/6小鼠随机分为低脂饮食(LFD)和高脂饮食

烧伤后颏颈胸瘢痕挛缩患者右美托咪定镇静纤支镜引导下经鼻气管插管的体会

颏、颈、胸重度烧伤患者,临床表现为颈部瘢痕挛缩严重,下颌与前胸瘢痕粘连,患者张口困难,后仰受限。此类患者存在面罩通气困难,声门显露困难,气道表麻困难等问题,严重影响手术,威胁患者健康,实施气管内插管对麻醉医生是严峻的挑战。山东大学附属省立医院麻醉科近期采用自制的OLYMPUSLF-DP型号纤支镜气道内表麻设备先实施气管内表麻,然后再使用右美托咪定镇静,纤支镜引导下成功完成经鼻气管插管,插管过程患者

18载研发人工真皮 35年坚守烧伤一线

“一个医生救治病人的能力有限,如果能从临床问题入手,通过基础研究和转化研究发明出技术、产品或理论体系,就能救治更多病人,产生更大价值。”秉承以上导向,浙江大学医学院附属第二医院(下称浙医二院)烧伤科主任韩春茂,从医35年来,对人工真皮的钻研已有18载。起伏18年从1983年进入医院起,韩春茂便主治创面,病人的痛苦呻吟让他记忆深刻。“痛到什么程度?有时候我们换药的小推车刚进病房门口,病人就害怕

拓展阅读

烧伤后的周围神经病变与神经卡压

烧伤引起的并发症有很多,周围神经的病变和神经卡压综合征也是烧伤后导致的一系列并发症之一。但是由于对烧伤患者采用了全面的疼痛控制方案,神经源性疼痛在临床上可能并不明显,所以今早的识别和治疗就显得尤为重要

Int Wound J:湿式敷料联合壳聚糖伤口敷料治疗深二度烧伤的临床疗效

由于皮肤屏障功能的破坏,烧伤患者的免疫功能下降。伤口细菌感染的风险很高,严重时甚至危及患者的生命安全。因此,烧伤患者应尽快进行合理治疗,促进伤口愈合,改善皮肤功能,避免病情进一步恶化。

Clin Nutrition:富含omega-3脂肪酸胶原蛋白的饮料对严重烧伤患者伤口愈合、代谢生物标志物的影响

烧伤(burns)泛指由热力(如火焰、热液、热蒸汽、热金属等)造成的伤害;化学物质(如酸、碱、磷等);以及电流、放射线、激光等所造成的组织损害和烧伤有类似表现,有皮肤损害时归入烧伤治疗范畴。

烧伤(烫伤)患者的紧急处置

一文读懂,烧伤知识点~

Burns:烧伤创口包扎前使用反射区按摩和音乐疗法可减轻患者的疼痛和焦虑感

烧伤患者因烧伤包扎而产生的疼痛、焦虑和睡眠障碍对其治疗过程产生了负面影响。近日,发表于Burns的一项随机对照试验探究了烧伤包扎前的反射按摩和被动音乐疗法干预对疼痛、焦虑程度和睡眠质量的影响。